Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Lancet Oncol. 2018 Aug 16;19(9):1229–1238. doi: 10.1016/S1470-2045(18)30426-1

Figure 1. Trial Diagram.

Figure 1.

Outcome for all patients enrolled on study. Subjects in both the Phase 1 (dose finding) and Phase 2 (complete response rate) portions are included. Subjects were treated at either dose level 1 (1.4 mg/kg/dose of Brentuximab vedotin) or dose level 2 (1.8 mg/kg/dose of Brentuximab vedotin). Results of primary outcomes and clinical outcomes are indicated.